Michael Eberhardson

Dr. Michael Eberhardson


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2019 in Critical Care
Verified
Journal Article
Open access
PDF file
EBEmily Brück
Emily Brück
JLJacob W. Larsson
Jacob W. Larsson
JLJulie Lasselin
Julie Lasselin
MBMatteo Bottai
Matteo Bottai
THTatja Hirvikoski
Tatja Hirvikoski
POPeder S. Olofsson
Peder S. Olofsson
Cognitive impairment and psychological distress are common in intensive care unit (ICU) survivors. Early identification of affected individuals is important, so intervention and treatment can be utilized at an early stage. Cognitive Failures Questionnaire (CFQ) is commonly used to screen for subjective cognitive function, but it is unclear whether CFQ scores correlate to objective cognitive function in this population. Between 2014 and 2018, 100 ICU survivors aged 18–70 years from the general ICU at the Karolinska University Hospital, Solna, were included in the study. Out of these, 58 patients completed follow-up at 3 months after ICU discharge, 51 at 6 months, and 45 at 12 months. Follow-up included objective cognitive function testing using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and subjective cognitive function testing with the self-rating Cognitive Failures Questionnaire (CFQ), as well as psychological self-rating with the Post-Traumatic Stress Symptoms Scale-10 (PTSS-10) and Hospital Anxiety and Depression Scale (HADS). The prevalence of cognitive impairment as measured by four selected CANTAB tests was 34% at 3 months after discharge, 18% at 6 months, and 16% at 12 months. There was a lack of significant correlation between CANTAB scores and CFQ scores at 3 months (r = − 0.134–0.207, p > 0.05), at 6 months (r = − 0.106–0.257, p > 0.05), and at 12 months after discharge (r = − 0.070–0.109, p > 0.05). Correlations between CFQ and PTSS-10 scores and HADS scores, respectively, were significant over the follow-up period (r = 0.372–0.710, p ≤ 0.001–0.023). In contrast, CANTAB test scores showed a weak correlation with PTSS-10 and HADS scores, respectively, at 3 months only (r = − 0.319–0.348, p = 0.008–0.015). We found no clinically relevant correlation between subjective and objective cognitive function in this cohort of ICU survivors, while subjective cognitive function correlated significantly with psychological symptoms throughout the follow-up period. Treatment and evaluation of ICU survivors’ recovery need to consider both subjective and objective aspects of cognitive impairment, and subjective reports must be interpreted with caution as an indicator of objective cognitive function.

28 July 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MEMichael Eberhardson
Michael Eberhardson
JSJ. K. Söderling
J. K. Söderling
MNM. Neovius
M. Neovius
TCT. Cars
T. Cars
PMP. Myrelid
P. Myrelid
OOO. Olén
O. Olén

22 April 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
BLBojing Liu
Bojing Liu
AWAlkwin Wanders
Alkwin Wanders
KWKarin Wirdefeldt
Karin Wirdefeldt
ASArvid Sjölander
Arvid Sjölander
MSMichael C. Sachs
Michael C. Sachs
JLJohnny Ludvigsson
Johnny Ludvigsson
Summary: Background: The vagus nerve provides essential parasympathetic innervation to the gastrointestinal system and is known to have anti‐inflammatory properties.Aims: To explore the relationship between vagotomy and the risk of inflammatory bowel disease (IBD) and its major categories: Crohn's disease (CD) and ulcerative colitis (UC).Methods: A matched cohort comprising 15 637 patients undergoing vagotomy was identified through the Swedish Patient Register from 1964 to 2010. Each vagotomised patient was matched for birth year and gender with 40 nonvagotomised individuals on the date of vagotomy. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for IBD using flexible parametric models adjusted for matching variables, year of vagotomy, birth country, chronic obstructive pulmonary disease and comorbidity index.Results: We observed 119 (0.8%) patients with vagotomy developed IBD compared to 3377 (0.5%) IBD cases in nonvagotomised individuals. The crude incidence of IBD (per 1000 person‐years) was 0.38 for vagotomised patients and 0.25 for nonvagotomised individuals. We observed a time‐dependent elevated risk of IBD associated with vagotomy, for instance, the HR (95% CI) was 1.80 (1.40‐2.31) at year 5 and 1.49 (1.14‐1.96) at year 10 post‐vagotomy. The association appeared to be stronger for truncal than selective vagotomy and limited to CD (HR was 3.63 [1.94‐6.80] for truncal and 2.06 [1.49‐2.84] for selective vagotomy) but not UC (1.36 [0.71‐2.62] for truncal and 1.25 [0.95‐1.63] for selective vagotomy).Conclusions: We found a positive association between vagotomy and later IBD, particularly for CD. The finding indirectly underlines the beneficial role of the vagal tone in IBD.

23 December 2018 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
MEMichael Eberhardson
Michael Eberhardson
CHCharlotte Hedin
Charlotte Hedin
MCMarie Carlson
Marie Carlson
LTLaura Tarnawski
Laura Tarnawski
YLYaakov A. Levine
Yaakov A. Levine
POPeder S. Olofsson
Peder S. Olofsson
Inflammatory bowel disease (IBD) is characterized by activation of both the innate and adaptive immune system in genetically susceptible individuals, resulting in chronic intestinal inflammation. The triggers that initiate and perpetuate this continuous inflammation are the subject of much speculation and research, although the central role of the intestinal microbiota is recognized, and is even a target for treatment in some circumstances. The mainstay of modern IBD treatment is suppression of the immune response towards as yet unspecified antigens, and conventional therapy includes corticosteroids, 5‐aminosalicylic acid (5‐ASA), thiopurines and methotrexate. Reducing activity of specific mediators has proven efficacious, including adhesion molecules, such as the gut‐homing integrin α4β7 expressed on the surface of circulating immune cells, and cytokines, such as tumour necrosis factor α (TNF‐α). This has been achieved using biologic agents including monoclonal antibodies. Recent discoveries in immunology and neuroscience have revealed that signals in the peripheral nervous system regulate inflammation, including levels of TNF‐α. The understanding of the mechanisms of the neuro‐immune communication involved in inflammation control in the gut is evolving, but is as yet incomplete. Clinical studies using implanted vagus nerve stimulators for treatment of IBD show encouraging results. Accordingly, the neural reflex control of inflammation is emerging as a potential therapeutic target in treatment of IBD. Here, we review current therapeutic options and neural reflex control of gut immunity in the context of intestinal inflammation.

Verified
Journal Article
Open access
PDF file
HRHelena J. Rolandsdotter
Helena J. Rolandsdotter
PMPer Marits
Per Marits
USUlf Sundin
Ulf Sundin
AWAnn-Charlotte Wikström
Ann-Charlotte Wikström
UFUlrika L. Fagerberg
Ulrika L. Fagerberg
MEMichael Eberhardson
Michael Eberhardson
The role of trough serum infliximab (s-IFX) and antibodies toward IFX (ATI) during maintenance treatment remains unclear in children. The aim of the present study was to investigate trough s-IFX and ATI to identify any correlation with inflammatory activity and clinical response in a pediatric inflammatory bowel disease (IBD) cohort. We investigated the s-IFX trough levels in pediatric IBD patients (n = 45) on maintenance IFX treatment. Ninety-three blood samples were collected and demographics, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and albumin were recorded. The mean s-IFX trough level was 5.2 µg/mL. The mean trough s-IFX level was significantly higher in the samples taken during remission (7.2 µg/mL) compared to active disease (4.5 µg/mL, p < 0.05). The trough s-IFX levels correlated with ESR, CRP, and albumin. S-IFX was undetectable in eight of the patients, all with positive ATI and active disease. Surprisingly, clinical and biochemical remission was observed at only 26 of the 93 visits. The correlation between dose variations and changes in trough s-IFX was not evident. In line with studies in adults, the s-IFX trough levels correlated with response to infliximab.

29 April 2021 in International Immunology
Verified
Journal Article
Open access
PDF file
MEMichael Eberhardson
Michael Eberhardson
YLYaakov A Levine
Yaakov A Levine
LTLaura Tarnawski
Laura Tarnawski
POPeder S Olofsson
Peder S Olofsson
The hallmark of inflammatory bowel diseases (IBD) is chronic intestinal inflammation with typical onset in adolescents and young adults. An abundance of neutrophils is seen in the inflammatory lesions, but adaptive immunity is also an important player in the chronicity of the disease. There is an unmet need for new treatment options since modern medicines such as biological therapy with anti-cytokine antibodies still leave a substantial number of patients with persisting disease activity. The role of the central nervous system and its interaction with the gut in the pathophysiology of IBD have been brought to attention both in animal models and in humans after the discovery of the inflammatory reflex. The suggested control of gut immunity by the brain–gut axis represents a novel therapeutic target suitable for bioelectronic intervention. In this review, we discuss the role of the inflammatory reflex in gut inflammation and the recent advances in the treatment of IBD by intervening with the brain–gut axis through bioelectronic devices.